GlassScriptPhysician profile
Allison B Walsh
NPI 1801107487
$4,139.85
in general payments reported to CMS, 2019-2025
38 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $222 · 2021: $494 · 2022: $1,021 · 2023: $872 · 2024: $916 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952 · Education: $93.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,952.43 |
| Education | $93.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.51 | 2019-2025 | Liletta, Botox, Orilissa |
| Lilly USA, LLC | $433.01 | 2022-2025 | Zepbound, Mounjaro |
| Amgen INC. | $432.43 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $403.06 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Mayne Pharma Commercial LLC | $233.72 | 2021-2024 | |
| Astellas Pharma US INC | $219.95 | 2022-2025 | Veozah |
| Evofem Biosciences, INC. | $207.07 | 2020-2025 | Phexxi, Solosec, Phexx |
| Hologic Sales and Service, LLC | $156.84 | 2020-2024 | Aptima, Thinprep 2000 Processor, Third Wave |
| Meditrina | $128.19 | 2021-2022 | |
| Therapeuticsmd, INC. | $123.58 | 2019-2022 | |
| Allergan, INC. | $104.39 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $102.52 | 2023-2024 | Myfembree |
| Radius Health, INC. | $97.65 | 2020-2024 | Tymlos |
| Exeltis, USA INC. | $94.46 | 2023-2025 | Slynd |
| Millicent US INC | $88.84 | 2024-2025 | Femlyv, Intrarosa |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $86.02 | 2021-2022 | |
| Myovant Sciences INC. | $80.91 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $79.43 | 2024 | Strensiq |
| Avion Pharmaceuticals | $77.26 | 2019-2023 | Balcoltra |
| Sage Therapeutics, LLC | $63.19 | 2024 | |
| Organon LLC | $56.90 | 2022-2024 | Nexplanon |
| Daiichi Sankyo INC. | $53.09 | 2019 | |
| Mylan Pharmaceuticals INC. | $52.32 | 2021-2022 | |
| Scynexis, INC. | $35.19 | 2022 | |
| Virtus Pharmaceuticals LLC | $31.55 | 2021 | |
| Coopersurgical, INC. | $24.91 | 2022 | |
| Boston Scientific Corporation | $23.10 | 2019 | |
| Lupin INC. | $20.47 | 2021 | |
| Impel Pharmaceuticals INC. | $19.01 | 2022 | |
| Minerva Surgical, INC | $17.68 | 2023 | |
| Optumhealth Care Solutions, LLC | $17.55 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Merck Sharp & Dohme LLC | $17.23 | 2021 | |
| Aesculap, INC. | $13.61 | 2019 | |
| Pfizer INC. | $13.17 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $13.00 | 2019 | |
| Currax Pharmaceuticals LLC | $12.01 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.98 | 2022 | |
| Olympus America INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.